Aelis Farma: Availability of the Description of the Share Buyback Program – Medical Marijuana Program Connection

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that the availability of the description of the share buyback program authorized by the Annual General Meeting of May 24, 2023. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized on May 24, 2023, in its

Source link